Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

White B et al. - Pharmacokinetic data coupled with higher-than-expected placebo clinical response rates may partly explain siplizumab’s marginal clinical activity. Higher doses of siplizumab may be required to detect significant improvements in psoriasis.

Related Articles

Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09    Relevance Score: 95%

FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09    Relevance Score: 91%

Study shows major burden of psoriasis
Internet Source, 10/29/09    Relevance Score: 91%

Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09    Relevance Score: 91%

Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09    Relevance Score: 91%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address